eligibility_summary
Eligibility: 18–70, new-onset TP53‑mutant DLBCL, ECOG 0–2, LVEF >45%, occult HBV carriers allowed only if HBV‑DNA negative, bilirubin ≤2× ULN, ALT/AST ≤2.5× ULN, creatinine ≤2× ULN, life expectancy ≥6 mo, consent. Exclude: primary/secondary CNS DLBCL, HIV+ or active HCV, major cardiovascular disease, severe COPD with hypoxemia, uncontrolled infection, other recent cancers (except basal cell skin, cervical in situ, early prostate/breast), allergy to murine proteins.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 2, single-arm ARCHOP for previously untreated TP53‑mutated DLBCL. Interventions: azacitidine (hypomethylating cytidine analog, DNA methyltransferase inhibitor → DNA hypomethylation, re-expression of silenced genes, pro‑apoptotic/chemo‑sensitization) plus R‑CHOP: rituximab (chimeric anti‑CD20 monoclonal antibody → ADCC/CDC/direct apoptosis of B cells), cyclophosphamide (alkylating agent → DNA crosslinking), epirubicin or liposomal doxorubicin (anthracycline → topoisomerase II inhibition/DNA intercalation), vincristine (vinca alkaloid → microtubule inhibition), prednisone (glucocorticoid → lymphocyte apoptosis). Targets/pathways: CD20+ malignant B cells, epigenetic DNA methylation (DNMT), DNA damage/repair and replication (alkylation/topo II), microtubules/mitosis, immune effector pathways (Fc/complement), glucocorticoid receptor–mediated apoptosis.